Di Claudio, in his thesis about endometriosis, also showed the possibility of identifying potentially ‘high-risk’ patients who present a significant upregulation of genes involved in reprogramming (e.g., SOX2, NANOG), cancer metabolism (e.g., TP53, KRAS), and epithelial–mesenchymal transition (e.g., TGF alpha and SNA11). The gene discussed is NANOG; the disease is cancer.